Open-Label Extension Study of De-immunized DI-Leu16-IL2 Immunocytokine Administered in Participants With B-cell NHL
Status:
Terminated
Trial end date:
2016-07-11
Target enrollment:
Participant gender:
Summary
This is an open-label extension study enrolling participants experiencing clinical benefit
following 6 cycles of DI-Leu16-IL2 while enrolled in the Alopexx Oncology Dose-Escalation
AO-101 study (NCT01874288). Participants will be permitted to continue to receive
DI-Leu16-IL2 at the same dose, schedule, and route of administration they received during
Study AO-101 (Main Study). Prior pre-treatment (for example, Rituximab) will continue as
before.